You just read:

Kezar Life Sciences Announces Initiation of Phase 1 Clinical Program for Lead Candidate KZR-616, a First-in-Class Immunoproteasome Inhibitor

News provided by

Kezar Life Sciences

Sep 13, 2016, 08:02 ET